Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients.

Leukemia research - 1 Jan 2023

Ball Somedeb, Aguirre Luis E, Jain Akriti G, Ali Najla Al, Tinsley Sara M, Chan Onyee, Kuykendall Andrew T, Sweet Kendra, Lancet Jeffrey E, Sallman David A, Hussaini Mohammad Omar, Padron Eric, Komrokji Rami S

Abstract excerpt

EZH2 mutations in myeloid neoplasms are loss of function type, and have been linked to poor overall survival (OS) in patients with myelodysplastic syndrome (MDS). However, the specific determinants of outcomes in EZH2-mutant (mut) MDS are not well characterized. In this single-center retrospective study, clinical and genomic data were collected on 1774 patients with MDS treated at Moffitt Cancer Center. In our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Chromosome Aberrations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enhancer of Zeste Homolog 2 Protein

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Myeloproliferative Disorders

Share to Prognosis

Share to Transcription Factors

Source

Identifiers

PMID: 36542963
DOI: 10.1016/j.leukres.2022.106999

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients.PMID 36542963Read ↗

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.Semantic proximity Read ↗

Clinical characteristics and prognostic analysis of gene mutations in Myelodysplastic SyndromeSemantic proximity Read ↗

Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.Semantic proximity Read ↗

Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.Semantic proximity Read ↗

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.Semantic proximity Read ↗

Acute myeloid leukaemia (AML) harbouring KMT2A-PTD: should it be considered as a myelodysplasia-related abnormality?Semantic proximity Read ↗

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Semantic proximity Read ↗

Genetics of myelodysplastic syndromes: new insights.Semantic proximity Read ↗

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.Semantic proximity Read ↗

Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic SyndromesSemantic proximity Read ↗

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.Semantic proximity Read ↗

Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2-mutated acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.